Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (HRMY) priced its initial public offering on Aug 20, 2020 at $24.00 per share, raising $128.4M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.53B. Goldman Sachs was lead-left underwriter, joined by Jefferies and Piper Sandler. Latham & Watkins advised the company and Goodwin Procter advised the underwriters.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on therapies for rare neurological disorders. Its product, WAKIX (pitolisant), approved by the FDA in August 2019 for excessive daytime sleepiness in adults with narcolepsy, works by increasing histamine signaling in the brain and is not a controlled substance.

Status

IPO

Ticker

HRMY

Exchange

Nasdaq Global Market

Priced

Aug 20, 2020

IPO price

$24.00

Raised

$128.4M

Market cap at IPO price

$1.53B

First filed

Jul 27, 2020

Underwriters

Goldman Sachs, Jefferies and Piper Sandler

Company counsel

Latham & Watkins

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.